Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Epigenetics can be defined as the study of chemical modifications of some specific genes of an organism. A gene can be altered with change in the sequence of its DNA or epigenetic programming. Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states.

Statistics:

The global epigenetic drugs and diagnostic technologies market is estimated to account for US$ 28,606.6 Mn in terms of value by the end of 2027.

Global Epigenetic Drugs and Diagnostic Technologies Market: Drivers

Increasing prevalence of cancer is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, R&D in epigenetic drugs is also expected to aid in growth of the market. For instance, the study, ‘Vorinostat in the acute neuroinflammatory form of X?linked adrenoleukodystrophy’, published in May 2020, in Annals of Clinical and Translational Neurology, reported that treatment with certain epigenetic medicines may help compensate for a deficiency in the ABCD1 gene in patients with adrenoleukodystrophy.

Statistics:

North America held dominant position in the global epigenetic drugs and diagnostic technologies market in 2019, accounting for 40.8% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Epigenetic Drugs and Diagnostic Technologies Market Share (%) Value, By Region, 2019

Epigenetics Drugs & Diagnostic Technologies  | Coherent Market Insights

Global Epigenetic Drugs and Diagnostic Technologies Market: Restraints

Longer durations of R&D for developing epigenetic drugs is expected to hinder growth of the market. It takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way.

Moreover, lack of evidence regarding the efficacy of epigenetic therapy in solid tumors is also expected to limit the market growth.

request-sample

Epigenetic Drugs and Diagnostic Technologies Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 6,800.3 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 19.7% 2027 Value Projection: US$ 28,606.6 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Type:
    • Epigenetic Drugs:
      • DNMT Inhibitors: Azacitidine, Decitabine.
      • HDAC Inhibitors: Vorinostat, Romidepsin.
    • Epigenetics Diagnostic Technologies: DNA Methylation, ChIP Technology
Companies covered:

4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.

Growth Drivers:
  • Increasing prevalence of chronic disorders
Restraints & Challenges:
  • Stringent Regulation

Global Epigenetic Drugs and Diagnostic Technologies Market: Opportunities 

Funding for R&D in epigenetics is expected to offer lucrative growth opportunities for players in the global epigenetic drugs and diagnostic technologies market. For instance, in June 2020, The University of Illinois at Chicago, U.S., received US$ 8.2 million from the National Institute on Alcohol Abuse and Alcoholism to continue the Center for Alcohol Research in Epigenetics and its research on how alcohol affects genes through epigenetics.

Moreover, development machine-learning algorithms to aid in epigenetic drug discovery is also expected to boost the market growth. For instance, in October 2019, researchers at Sanford Burnham Prebys Medical Discovery Institute, U.S, developed a machine-learning algorithm that gleans information from microscope images in order to allow high-throughput epigenetic drug screens.

Statistics:

The global epigenetic drugs and diagnostic technologies market was valued at US$ 6,800.3 Mn in 2019 and is forecast to reach a value of US$ 28,606.6 Mn by 2027 at a CAGR of 19.7% between 2020 and 2027.

Figure 2: Global Epigenetic Drugs and Diagnostic Technologies Market Value (US$ Mn), 2016 – 2027

Epigenetics Drugs & Diagnostic Technologies  | Coherent Market Insights

Market Trends/Key Takeaways

The market is witnessing R&D of novel epigenetic drugs. For instance, in November 2019, researchers with the Pasteur Institute and CNRS (French National Center for Scientific Research), France, reported identifying epigenetic inhibiting drugs that can inhibit DNA methylation and eliminate even the most resistant of the malaria parasites, Plasmodium falciparum, in the journal ACS Central Science.

The market is also witnessing entry of new players. For instance, in September 2019, Omega Therapeutics, a biotech startup, announced its entry in R&D of medicines based on epigenetics.

Global Epigenetic Drugs and Diagnostic Technologies Market: Competitive Landscape

Major players operating in the global epigenetic drugs and diagnostic technologies market include, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.

Global Epigenetic Drugs and Diagnostic Technologies Market: Key Developments

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in July 2020, EpiGentek launched a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic.

Major players in the market are also focused on adopting collaboration strategies to expand their product portfolio. For instance, in June 2020, Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics for R&D of new therapies, collaborated with Institute of Medical and Molecular Genetics (INGEMM) of the La Paz University Hospital in Madrid for R&D of precision medicine in patients with Phelan-McDermid Syndrome.

Epigenetic is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of disease such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel the market growth during the forecasted period.

Key features of the study:

  • This report provides in-depth analysis of the Global Epigenetic Drugs and Diagnostic Technologies market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Epigenetic Drugs and Diagnostic Technologies market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Epigenetic Drugs and Diagnostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Epigenetic Drugs and Diagnostic Technologies market

Detailed Segmentation:

  • Global Epigenetic Drugs and Diagnostic Technologies Market, By Type:
    • Epigenetic Drugs
      • DNMT Inhibitors
        • Azacitidine
        • Decitabine
      • HDAC Inhibitors
        • Vorinostat
        • Romidepsin
    • Epigenetics Diagnostic Technologies
      • DNA Methylation
      • ChIP Technology
  • Global Epigenetic Drugs and Diagnostic Technologies Market, By Region:
    • North America
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
          • ChIP Technology
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
        • ChIP Technology
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
        • ChIP Technology
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
        • ChIP Technology
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
        • ChIP Technology
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Epigenetic Drugs
          • DNMT Inhibitors
            • Azacitidine
            • Decitabine
          • HDAC Inhibitors
            • Vorinostat
            • Romidepsin
        • Epigenetics Diagnostic Technologies
          • DNA Methylation
        • ChIP Technology
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • 4SC AG *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Acetylon Pharmaceuticals, Inc.
    • Astex Pharmaceuticals Inc.
    • CellCentric Ltd.
    • Celleron Therapeutics Ltd.
    • Celgene Corporation
    • Chroma Therapeutics Ltd.
    • Epigentek Group Inc.
    • Eisai Co. Ltd.
    • EnVivo Pharmaceuticals Inc.
    • Base Genomics
    • Oryzon Genomics, S.A.
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on market
  4. Global Epigenetic Drugs and Diagnostic Technologies Market, By Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Epigenetic Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • DNMT Inhibitors
          • Azacitidine
          • Decitabine
        • HDAC Inhibitors
          • Vorinostat
          • Romidepsin
    • Epigenetics Diagnostic Technologies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • DNA Methylation
        • ChIP Technology
  5. Global Epigenetic Drugs and Diagnostic Technologies Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • 4SC AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acetylon Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Astex Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CellCentric Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celleron Therapeutics Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Chroma Therapeutics Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Epigentek Group Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eisai Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • EnVivo Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Base Genomics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Oryzon Genomics, S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 14 figures on “Epigenetic Drugs and Diagnostic Technologies Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Epigenetic Drugs and Diagnostic Technologies market size was valued at US$ 6,800.3 million in 2019 and is estimated to exhibit a CAGR of 19.7% between 2020 and 2027.
Epigenetic Drugs segment held the major market share in 2019 owing increasing prevalence of cancer over the forecast period.
Major factor driving the growth of Global Epigenetic Drugs and Diagnostic Technologies market during the forecast period increasing prevalence of cancer, increasing research and development, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Epigenetic Drugs and Diagnostic Technologies market during the forecast period constitutes of stringent regulatory guidelines.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner